BI_1463-0001: An open label, Phase I dose-finding and expansion study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers, and BI 765179 in combination with pembrolizumab in first-line PD-L1-positive metastatic or incurable, recurrent head and neck squamous cell carcinoma (HNSCC)

Objective

Clinical Trial Details

Principal Investigator(s)

Benjamin Solomon, MD

Clinical Trial Categories

• Cancer
• Head and Neck Cancer

Contact

Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org